PSN 821

Drug Profile

PSN 821

Alternative Names: PSN821

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Prosidion
  • Class Antihyperglycaemics; Small molecules; Sulfoxides
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 04 Feb 2013 Discontinued - Phase-I for Obesity in United Kingdom (PO)
  • 04 Feb 2013 Discontinued - Phase-II for Type-2 diabetes mellitus in Germany (PO)
  • 04 Feb 2013 Discontinued - Phase-II for Type-2 diabetes mellitus in South Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top